Viral Hepatitis C is the most common cause of the End Stage Liver Disease in Egypt. In this study we assess the clinical progress, recurrence and the management of the hepatitis C Patients who underwent Living Donor Liver Transplantation.
72 patients were transplanted from October 2001 till December 2004 , They were 14 child and 58 adult, Mortality rate was 25 patients (34%) , 21 patients of them died early post operative. This study was done on 34 HCV infected Recipient, 11 patients of them acquired HCV recurrence, 9 % of them acquired recurrence within the first 3 months, 45 % within 3-6 months, 28 % within 6-9 months and 18 % within 9-12 months. 4 patients from the 11 Recurrent Patients (32.5%) were receiving immunosuppressant in the form of dual therapy consists of mycophenolate mofetil and Neoral, while 7 patients were receiving mycophenolate mofetil and tacrolimus . All Recurrent patients were given pegylated interferon plus Ribavirin as treatment for HCV recurrence, while 72 % of recurrent patients were given colony stimulating factor as a treatment of neutropenia cause by the adverse effect of the pegylated INF.
We observed that the HCV Genotype IV recurrence rate of a living donor transplanted liver was high (32.5) The prevention of HCV recurrence and the management of post recurrent cirrhotic changes are crucial for the graft and patient survival. Modification of Immunosuppressants may be needed in LDLT specially in HCV Genotype IV.